It’s unclear what impact a change in presidential administration will have on the proposal to widen access for those with obesity.

Concerns have been raised by senior doctors surrounding the misuse of weight-loss pens in the UK, with some patients ...

With expected sales for GLP1Rs in obesity estimated to surpass $126 billion by 2030, this drug category presents a lucrative ...

President-elect Donald Trump, a Biden administration proposal would require Medicare and Medicaid to cover weight-loss drugs ...

Shares of Eli Lilly LLY and Novo Nordisk NVO were up on Tuesday, likely due to a proposal by President Biden that Medicare ...

Mounjaro is a treatment for Type 2 diabetes that activates GIP and GLP-1 pathways to help regulate blood sugar. It’s part of ...

Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...

The stocks of companies that make the new class of drugs to treat obesity and manage diabetes were higher across the board ...

That increased convenience will have to be accompanied by weight loss that is at least as effective as its rivals, and Amgen ...

Pharmaceutical stocks make great additions to any portfolio in any market environment. A good one promises steady revenue ...

The Biden administration plans to require Medicare and Medicaid to offer coverage of weight loss medications for people seeking obesity treatment.The new rule, which was proposed by the administration ...

About 42% of U.S. adults are obese, the CDC says. GLP-1 medications have changed the picture for people hoping to reduce ...